Drug intelligence / Profile preview

PSB202

Development stage: Phase 1
Lead developer: Qilu Puget Sound Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**PSB202** is an investigational, fixed-ratio MabPair antibody combination comprising two separately engineered humanized IgG1 monoclonal antibodies: Fc-enhanced type II anti-CD20 antibody PSB102 and anti-CD37 antibody PSB107. The two antibodies are co-produced from a single CHO cell line at a defined 1:1 molecular ratio and are intended to deplete CD20- and CD37-expressing malignant B cells through direct target-mediated killing, enhanced antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. It is being evaluated by Sound Biologics and Qilu Pharmaceutical in relapsed or refractory indolent B-cell malignancies, including B-cell non-Hodgkin lymphoma. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd20-cd37-monoclonal-antibody-combination-psb202))

Other names: anti-CD20 monoclonal antibody/anti-CD37 monoclonal antibody combination PSB202anti-CD20/anti-CD37 monoclonal antibody combination PSB202PSB102 + PSB107

Targets

CD20 (B-lymphocyte antigen CD20)CD37

Beyond the preview

Go deeper on PSB202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB202.

Explore the full profile